Influenza Clinical Trial
Official title:
Randomized Trial of Peer-to-Peer Versus Pharmacist Education to Improve Older Adults' Vaccination Knowledge Through the Senior Center Model of Care
The study consists of two arms (PHARM and PEER) designed to educate participants about three vaccine-preventable diseases (zoster, pneumonia, and influenza) and vaccination. PHARM will consist of a 60-minute presentation about the three vaccine-preventable diseases and their vaccinations delivered by a pharmacist, featuring a didactic lecture and discussion supplemented by video clips of community members discussing their experiences around vaccination, as well as physicians underscoring the importance of vaccination. PEER will consist of a 60-minute small-group session led by a peer educator which includes scripted roleplaying exercises designed to reinforce learnings pertaining to these three vaccine-preventable diseases and their vaccinations. The components of these interventions will be designed to address specific barriers to vaccination identified by literature search and our prior work in the area of community-based vaccine education. Both arms will focus primarily on pneumococcal disease and zoster but will include limited content on influenza because participants are likely to have questions about how the flu and its vaccination differ from pneumococcal diseases and zoster. The study will be implemented in an older, predominantly African-American (AA) population, consistent with our prior work in this area.
In the pharmacist-led ("PHARM") intervention group, participants will be given a 60-minute
formal didactic presentation on vaccine-preventable diseases and vaccination. This
presentation will be designed to address knowledge and beliefs related to zoster, pneumonia,
and influenza, as well as barriers to receiving vaccination. It will be delivered by a
pharmacist, will be appropriate for the participants' educational level, and will aim to
establish an understanding of vaccine-preventable illnesses. The presentation will
specifically discuss the following: causes, symptoms and potential complications of
infections in the three diseases of interest (pneumococcal disease, zoster, and influenza);
risk factors for developing the infections; incidence and prevalence of each disease of
interest; modes of transmission; and disease prevention through vaccination. To improve the
interactivity of the presentation, brief 30-60 second video clips excerpted from interviews
with community members and physicians will be shown. Community member clips will consist of
older adults from the African-American (AA) population who have experienced
vaccine-preventable infections. These clips will provide culturally relevant testimony to the
program audience and reinforce participant understanding of concepts introduced during
didactic teaching.
In the peer-led ("PEER") intervention, peer educators will be recruited from an experienced
cohort of peer educators at our senior center partner site. A pharmacist will train the peer
educators about vaccine-preventable diseases over the course of two didactic sessions.
Following this training, a third session will be held to train the peer educators on the
script that they will deliver to participants. The script will include the key learning
points to be taught by the peer educators to participants about vaccine preventable diseases
and vaccination. The script will also include roleplay exercises. In the roleplay exercises,
3 scripted vaccination-related scenarios (one for each disease of interest) will be acted out
by participants to illustrate scenarios participants might encounter when interacting with
healthcare providers or friends/family. The skit and roleplay exercises will be practiced as
needed, under the leadership of the senior center's project manager, to ensure that the peer
educators are confident and consistent when delivering PEER. After completing the training,
peer educators' competency on PEER program content will be assessed through a formal
multiple-choice knowledge test. Each peer educator must achieve a minimum score of 80%
correct over all items assessed, and 100% correct for all items deemed "core" knowledge. Once
peer educator competency has been established, each peer educator will deliver PEER through a
60-minute small group session. During this session, peer educators will deliver the
educational objectives through an informal discussion and will lead the group through the
roleplay exercises. Participants will then be asked what key points they learned about
vaccine-preventable diseases and vaccines. Finally, the peer educator will engage in a
dialogue to clarify and summarize these key points.
Objectives are:
1. Compare the efficacy of PHARM vs. PEER at improving participant's knowledge regarding
vaccine-preventable diseases
2. Compare the efficacy of PHARM vs. PEER at improving participants' beliefs about
vaccination
3. Measure the costs of PHARM and PEER from the senior center perspective
4. Compare the percent of participants taking activation step(s) to get vaccinated
following receipt of PHARM vs. PEER
5. Determine the extent to which participants are satisfied with and trust the PHARM vs.
PEER interventions
Hypotheses supporting these objective are:
1. PHARM and PEER will achieve similar improvements in older adults' knowledge of vaccine
preventable diseases (primary hypothesis)
2. PHARM and PEER will improved beliefs about vaccine-preventable disease
3. PEER will be a lower cost approach to educating participants in the senior center
compared to PHARM
4. PHARM and PEER will result in similar rates of participants taking one or more
activation step(s) to obtain vaccination
5. Participants will be highly satisfied with the PHARM and PEER interventions
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |